Elderly patients with advanced non-small-cell lung cancer (NSCLC) are usually excluded from most clinical trials because of the toxicity associated with chemotherapy. About 50\% of the new cases of lung cancer occur in patients older than 65 years. Doxifluridine is a fluoropyrimidine derivate which can be administered orally with very low toxicities. This phase II study evaluates the toxicity and activity of a home therapy with oral doxifluridine in elderly advanced NSCLC patients. Thirty-three advanced NSCLC patients, aged 70 years or more, entered the study; median ECOG performance status was 1 (0-2) and 22 patients (66.6\%) had metastatic disease. Doxifluridine was given orally in three divided doses, for a total daily dose of 2,250 mg, for 4 consecutive days every week. The treatment was well tolerated; five patients (15\%) experienced a grade 3 diarrhea which required doxifluridine dose reduction to 1,500 mg daily. Thirty-one patients are evaluable for response; four partial responses (12.9\%) have been observed (95\% confidence limit interval 3.6-29.8\%); 17 patients (54.8\%) had a stabilization of the disease. This study demonstrates that a home therapy with oral doxifluridine in elderly NSCLC patients is feasible and well tolerated and should encourage further studies.
|Data di pubblicazione:||1996|
|Titolo:||Phase II study of oral doxifluridine in elderly patients with advanced non-small-cell lung cancer.|
|Autore/i:||E. Baldini;C. Tibaldi;E. Pfanner;S. Ricci;A. Falcone;A. Ceribelli;R. Sarcina;G. Comella;C. G. Stampino;P. F. Conte|
|Codice identificativo ISI:||WOS:A1996VT71600013|
|Codice identificativo Scopus:||2-s2.0-10544228129|
|Citazione:||Phase II study of oral doxifluridine in elderly patients with advanced non-small-cell lung cancer. / E. Baldini;C. Tibaldi;E. Pfanner;S. Ricci;A. Falcone;A. Ceribelli;R. Sarcina;G. Comella;C. G. Stampino;P. F. Conte. - In: AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS. - ISSN 0277-3732. - STAMPA. - 19(1996), pp. 592-594.|
|Tipologia||Articolo su rivista|
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris